ZDNet UK


Skip to Main Content

ZDNet.co.uk - Winner of Best Business Website 2007
  1. Home
  2. News
  3. Blogs
  4. Reviews
  5. Prices
  6. Resources
  7. Community
  8. My ZDNet

 

ZDNet UK RSS Feeds


IT Jobs

Industry watch Toolkit

Google invests in biotech start-up

Dawn Kawamoto CNET News.com

Published: 23 May 2007 10:20 BST

  • Email
  • Trackback
  • Clip Link
  • Print friendly
  • Post Comment

Google has invested $3.9m (£1.9m) in 23andMe, a biotech start-up co-founded by the wife of Google co-founder Sergey Brin, according to a filing with the Securities and Exchange Commission on Tuesday.

With its investment, Google will hold a minority stake in 23andMe, co-founded last year by Anne Wojcicki. The company focuses on aiding consumers in understanding their genome.

Blog contest

Win tickets for England v West Indies

Anyone for cricket? ZDNet UK is giving away two tickets every day of the npower second test at Headingley Carnegie. Just take part in the Vista Upgrade Blog to enter.

Read more+

The search giant was one of several investors in a series A, or first round, of funding for the biotech company. Other investors include New Enterprise Associates, Mohr Davidow Ventures and biotech giant Genentech. Terms of the financing deal were not disclosed.

Genentech's chief executive, Arthur Levinson, sits on Google's board, and the search giant had its audit committee review the transaction as part of its policy for assessing deals to avoid potential conflicts of interest. The audit committee, which approved the transaction, also received advice from an independent counsel and financial adviser on the valuation of the deal.

Prior to Google's investment, Brin had provided approximately $2.6m (£1.3m) in interim debt financing to 23andMe. He was repaid with proceeds from the series A financing.

Brin withdrew himself from all discussions regarding the investment, said Google spokesman Jon Murchinson. He also said it was premature to discuss whether Google would eventually partner with 23andMe, but that the investment was strategic to Google's business objectives.

"We made the investment because we think there is value in the work they plan to do in genetics," he said. "Our mission is to organise the world's information, and we think 23andMe developing new ways of helping people make sense of their genetic information will help further our mission."

  • Email
  • Trackback
  • Clip Link
  • Print friendly Print with Dell

Did you find this article useful?
4 out of 4 people found this useful


Full Talkback thread

1 comment

  1. Ehh??? 204357

Company/Topic Alerts

Create a new alert from the list below:





Related Jobs

Application Support - Team Lead - Structured Products - Perm - London

Call Sachin Gupta at Huxley Associates 0207 469 5151. Liaising with the Front Office traders you must have excellent communication skills and ...

Development Team Lead for Financial Software House

The particular product they build is a fund management tool that deals with cross asset modelling within the investment and fund management space. ...

Transaction Services Project/Programme Manager, London, Global

Transaction Services Project/Programme Manager, London, Global As part of a huge strategic Transaction Services expansion one of our Global Tier 1 ...

Discussions

pjc158 pjc158

Will Drizzle rain on Sun's MySql

Friday 25 July 2008, 5:30 PM

1 comment
pjc158 pjc158

Show me the money!

Friday 25 July 2008, 5:18 PM

5 comments

Featured Talkback

When all is said, if Microsoft produce the best product people will buy it and thats a good thing. If people have to buy their product because no one else can produce an alternative, only because interoperability protocols are kept secret, then thats a bad thing.

By: pround

Read full story:
EU court crushes Microsoft's antitrust appeal